Sterling Capital Management
IRD icon

Sterling Capital Management’s Opus Genetics IRD Stock Holding History

Sterling Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.1K Buy
2,296
+2,108
+1,121% +$8.76K ﹤0.01% 2478
2026
Q2 		$773 Buy
+188
New +$877 ﹤0.01% 3174

Other funds holding IRD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Sterling Capital Management's IRD Position: Q3 2026 in Review

Sterling Capital Management increased its Opus Genetics (IRD) stake by 1,121% in Q3 2026, buying an estimated $8.76K and bringing the position to 2,296 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2478.

Sterling Capital Management first reported a position in IRD in Q2 2026 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Sterling Capital Management held 2,296 shares of Opus Genetics worth $11.1K as of Q3 2026.
  • Sterling Capital Management bought 2,108 Opus Genetics shares in Q3 2026, an estimated $8.76K.
  • Opus Genetics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2478 holding.
  • Sterling Capital Management first reported a position in Opus Genetics in Q2 2026 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.